Abrogation of CD27 expression on Tregs showed synergistically enhanced anti-tumor immunity unleashed by PD-1 blockade, suggesting that targeting Treg-expressed CD27 might be a promising therapeutic strategy to enhance the efficiency of checkpoint inhibition therapy. The gene discussed is CD27; the disease is neoplasm.